pharmacokinetics of glp-1 receptor agonists and the kidney: from physiology to pharmacology and outcomes in diabetes Pharmacodynamic and pharmacokinetic profiles of
Description
Background Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis
They modulate central neural pathways and peripheral metabolic processes, providing cardiometabolic benefits beyond weight reduction
In clinical trials, it led to a weight reduction of up to 16.2%
Understanding these conflicts helps ensure safe, successful treatment with semaglutide or tirzepatide
95% CI 0.94, 1.03)
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has...
